In neuromyelitis optica spectrum disorder (NMOSD), no blood tests to evaluate disease activity, attack severity, or therapy impact have been developed. For a study, the researchers determined the effects of inebilizumab...Read More
Search Results for: Neuromyelitis optica spectrum disorder
EBI2-expressing B cells in neuromyelitis optica spectrum disorder with AQP4-IgG: Association with acute attacks and serum cytokines.
Jul 8, 2021
Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) is important in regulating B cell activation. We investigated whether EBI2 expression on B cells is associated with acute attacks in neuromyelitis optica spectrum...Read More
Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
Jul 5, 2021
When the novel coronavirus disease 2019 (COVID-19) appeared, concerns about its course in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) arose. This study aimed to evaluate the...Read More
Nov 20, 2020
This study was done to compare the specificity, sensitivity, and diagnostic accuracy of the three different sets of NMOSD criteria in patients presenting with inflammatory disorders of the central nervous system suggestive of...Read More
Safety and efficacy of azathioprine and tocilizumab in highly relapsing neuromyelitis optica spectrum disorder (NMO)
Aug 7, 2020
Neuromyelitis optica (NMO) is a central nervous system disorder that affects the eye nerves and spinal cord. Azathioprine is the recommended first-line treatment for NMO, and tocilizumab has been reported to reduce the NMO...Read More